Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22

1.

The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS.

Diabetes Prevention Program Research Group..

Diabetes Care. 2012 Apr;35(4):723-30. doi: 10.2337/dc11-1468. Erratum in: Diabetes Care. 2013 Dec;36(12):4173-5.

2.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
3.
4.

Targeting the consequences of the metabolic syndrome in the Diabetes Prevention Program.

Goldberg RB, Mather K.

Arterioscler Thromb Vasc Biol. 2012 Sep;32(9):2077-90. doi: 10.1161/ATVBAHA.111.241893. Review.

5.

Cost-effectiveness of rosiglitazone combination therapy for the treatment of type 2 diabetes mellitus in the UK.

Beale S, Bagust A, Shearer AT, Martin A, Hulme L.

Pharmacoeconomics. 2006;24 Suppl 1:21-34. Review.

PMID:
16800160
6.

Lifetime health consequences and cost-effectiveness of rosiglitazone in combination with metformin for the treatment of type 2 diabetes in Spain.

Shearer AT, Bagust A, Ampudia-Blasco FJ, Martínez-Lage Alvarez B, Pérez Escolano I, París G.

Pharmacoeconomics. 2006;24 Suppl 1:49-59. Review.

PMID:
16800162
7.

Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement.

Avenell A, Broom J, Brown TJ, Poobalan A, Aucott L, Stearns SC, Smith WC, Jung RT, Campbell MK, Grant AM.

Health Technol Assess. 2004 May;8(21):iii-iv, 1-182. Review.

8.

The potential of metformin for diabetes prevention.

Slama G.

Diabetes Metab. 2003 Sep;29(4 Pt 2):6S104-11. Review.

PMID:
14502107
9.

Review of models used in economic analyses of new oral treatments for type 2 diabetes mellitus.

Asche CV, Hippler SE, Eurich DT.

Pharmacoeconomics. 2014 Jan;32(1):15-27. doi: 10.1007/s40273-013-0117-7. Review.

PMID:
24357160
10.

An update on the Diabetes Prevention Program.

Ratner RE; Diabetes Prevention Program Research..

Endocr Pract. 2006 Jan-Feb;12 Suppl 1:20-4. Review.

11.

Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.

Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S.

Health Technol Assess. 2010 Jul;14(36):1-248. doi: 10.3310/hta14360. Review.

12.

Cost effectiveness of combination therapy with pioglitazone for type 2 diabetes mellitus from a german statutory healthcare perspective.

Neeser K, Lübben G, Siebert U, Schramm W.

Pharmacoeconomics. 2004;22(5):321-41. Review.

PMID:
15061682
13.

Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.

Shepherd J, Jones J, Takeda A, Davidson P, Price A.

Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. Review.

14.

Diabetes prevention programs.

Ramachandran A, Snehalatha C.

Med Clin North Am. 2011 Mar;95(2):353-72, viii. doi: 10.1016/j.mcna.2010.11.006. Review.

PMID:
21281838
15.

Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation.

Czoski-Murray C, Warren E, Chilcott J, Beverley C, Psyllaki MA, Cowan J.

Health Technol Assess. 2004 Apr;8(13):iii, ix-x, 1-91. Review.

16.

Prevention of type 2 diabetes: risk status, clinic, and community.

Narayan KM, Williamson DF.

J Gen Intern Med. 2010 Feb;25(2):154-7. doi: 10.1007/s11606-009-1148-9. Review.

17.

Economic Evaluation of Combined Diet and Physical Activity Promotion Programs to Prevent Type 2 Diabetes Among Persons at Increased Risk: A Systematic Review for the Community Preventive Services Task Force.

Li R, Qu S, Zhang P, Chattopadhyay S, Gregg EW, Albright A, Hopkins D, Pronk NP.

Ann Intern Med. 2015 Sep 15;163(6):452-60. doi: 10.7326/M15-0469. Review.

18.

Therapeutic Challenges in Diabetes Prevention: We Have Not Found the "Exercise Pill".

Srinivasan S, Florez JC.

Clin Pharmacol Ther. 2015 Aug;98(2):162-9. doi: 10.1002/cpt.146. Review.

19.

Design of a family-based lifestyle intervention for youth with type 2 diabetes: the TODAY study.

TODAY Study Group..

Int J Obes (Lond). 2010 Feb;34(2):217-26. doi: 10.1038/ijo.2009.195. Review.

20.

Metformin for prediabetes.

[No authors listed]

Med Lett Drugs Ther. 2016 Nov 7;58(1507):141. Review. No abstract available.

PMID:
27805573

Supplemental Content

Support Center